Compare Salesforce Inc (CRM) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Heron Therapeutics Inc — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Salesforce Inc is far larger — about 2756.7× Heron Therapeutics Inc's market cap, and Salesforce Inc pays a 0.77% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Heron Therapeutics Inc for 35 Days on average.
| CRM | HRTX | |
|---|---|---|
Market Cap | $187.48B | $68.01M |
Volume | 6,155,822 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $266.23 | $1.49 |
52-Week Low | $150.12 | $0.27 |
Typical Hold Time | 89 Days | 35 Days |
Enterprise Value | $217.82B | $174.75M |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% today, but remains under technical pressure with a bearish signal. The company demonstrates strong fundamentals with consistent earnings beats, 77.28% gross margins, and 21.99% net income margins. Recent AI-driven growth initiatives show promise, with Agentforce and Data 360 ARR reaching $2.9 billion. However, the stock faces headwinds from broader software sector weakness and AI disruption concerns.
The investment case balances strong profitability and AI monetization potential against sector-wide pressures. With 76.5% analyst buy ratings and a $271.91 consensus target offering 19% upside, the stock appears fundamentally undervalued. Key risks include AI competition, macroeconomic sensitivity, and the recent 35% YTD decline testing investor patience despite solid financial performance.
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
